Background {#Sec1}
==========

Certain metals are required for the normal physiological functions in living organisms. Since the past decade, there has been increase in the use of metal based NPs in bio-medical applications, exponential use of NPs alerts the safety concerns to reduce and/or prevent NP induced adverse effects on the living system \[[@CR1]\]. Among NPs, Cu and ZnO are generally found in the food supplements and human body \[[@CR2], [@CR3]\]. Unique physiochemical properties of Cu and ZnONPs attain functional applications in physiological metabolic processes, thus increasing their commercial value in industries \[[@CR4]--[@CR6]\]. However, adverse effects, including hemolysis, gastrointestinal distress, and liver and kidney damage were observed upon excess intake of Cu and ZnONPs \[[@CR7]\].

Particularly, the absorption of CuNPs is readily takes place after the ingestion, inhalation and the dermal exposure \[[@CR8], [@CR9]\], significantly through the gastrointestinal tract \[[@CR8], [@CR10]\]. CuNPs target mucosal cells and retain inside by bonding with metallothionein or glutathione \[[@CR11]\]. It is stored primarily in the liver, brain, heart, kidney and muscles. It was reported, 98% of Cu binds with Ceruloplasmin, a serum protein which lead to cellular toxicity. \[[@CR12], [@CR13]\].Cu is a catalytic inducer of superoxide radicals, hydroxyl radicals and hydrogen peroxide via the Haber-Weiss reaction \[[@CR14]\], higher concentrations of Cu may cause oxidative induced stress.

Based on the extent of solubility ZnONPs were being considered as separate group of NPs within the metal oxide NPs \[[@CR15]\]. Zinc element is found in human body and ZnONPs are known to be of lower toxic \[[@CR3]\]. However, excessive zinc is reported to induce toxic effects \[[@CR16]\]. Release of metallic cations Zn^2^from ZnONPs are also proved to be toxic in micro-organisms and rodents \[[@CR17]\]. ZnO NPs might enter via different routes to reach blood flow and induce adverse impacts on organs \[[@CR18]\]. Preliminary results indicated ZnONPs affected organ systems may show inflammation, altered heart rate and functions, and oxidative stress \[[@CR19], [@CR20]\]. According to \[[@CR21]\], inhalation of 20 nm ZnONPs (2.5 mg/kg bw) by rats twice a day resulted in an increased Zn content in the liver after 12 h and in kidneys after 36 h.

Increased awareness towards nanotoxicity, studies have been reported on the in vivo toxicity of CuNPs and ZnONPs for intranasal instillation \[[@CR22], [@CR23]\], intratracheal instillation \[[@CR24], [@CR25]\] and oral administration \[[@CR26]--[@CR28]\], dermal exposure \[[@CR29], [@CR30]\]. In order to evaluate the toxicity intravenous (i/v) and intraperitoneal (i/p) administration needs has to be performed. To our knowledge, minimal reports are available on CuNPs and ZnONPs toxicity for intravenous and intraperitoneal administration. Moreover, the toxicological mechanism and tissue distribution of the two NPs have not yet been systematically studied on following i/v and i/p injection.

Hereby, we demonstrated the toxicity of 16-96 nm ranged biosynthesized CuNPs and ZnONPs in male wistar rats through intraperitoneal (i/p) and intravenous (i/v) injectionsat the desired on 14th and 28th day of observation.

Method {#Sec2}
======

Biosynthesis of bio-CuNPs and bio-ZnONPs {#Sec3}
----------------------------------------

Biological synthesis of CuNPs and ZnONPs from non-pathogenic *Enterococcus faecalis* was adapted by extracellular enzymatic method \[[@CR31], [@CR32]\]. Further, the shape and size of synthesized nanoparticles were confirmed using field emission scanning electron microscopy (FeSEM) and transmission electron microscopy (TEM).

In vivo studies {#Sec4}
---------------

### Experimental animals and animal husbandry {#Sec5}

Specific disease-free, 12- to 13-week-old male Wistar rats were purchased from Mahaveera Enterprises, Hyderabad, India. Animals were selected within a weight range of 160--200 g for each group and acclimatized for 1 week prior to the initiation of treatment, and health status of rats was monitored daily. The animals were housed under standard conditions of temperature (24 ± 1 °C) and relative humidity (55 ± 10%) respectively, in 12-h light/dark cycles. During treatment, animals were housed in cages with stainless steel mesh lids. Animals were fed with commercially available standard pellet diet (VRK Nutrition Solutions, Sangli, Maharashtra, India Ltd.). Drinking water was supplied to the animals, ad libitum.

Toxicity studies were performed at Luqman College of Pharmacy, Kalaburagi, India. Animal handling was performed according to Good Laboratory Practice. The study protocol was approved by Institute Animals Ethics Committee (Approval number: 346/CPCSEA).

### Preparation and Administration of Bio-Cu and ZnONPs {#Sec6}

The stock suspensions of Bio-CuNPs and Bio-ZnONPs (50 mg/ml) were prepared by dissolving separately in double distilled water for overnight and were filtered using 0.22 μ syringe filters. Filtrates are used to prepare the working standard ranging from 1.25-175 μg/ml concentration.

Animals were divided into three groups of three different concentrations for each nanoparticle type. Considering six rats/group for intravenous route (coded as experiment A set) and six rats/group for intraperitoneal route (coded as experiment B set), as per Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. In both experiment sets *group A* served as control (vehicle distilled water).Table 1Intravenous route of administration of three different concentrations for each Biogenic nanoparticles: experiment (A)Group II: Bio-CuNP (μg/kg)Group III: Bio-ZnONPs (μg/kg)Group B (NOAEC) 6.1Group B (NOAEC) 11.14Group C (IC~50~) 9.5Group C (IC~50~) 13.7Group D (TLC) 11.7Group D (TLC) 16. 21Table 2Intraperitoneal route of administration of three different concentrations for each Biogenic nanoparticles: experiment (B)Group II: Bio-CuNP (μg/kg)Group III: Bio-ZnONPs (μg/kg)Group B (NOAEC) 13.41Group B (NOAEC) 24.8Group C (IC~50~) 16.75Group C (IC~50~) 27.2Group D (TLC) 19.82Group D (TLC) 30.3*NOAEC* "no observable adverse effect concentration", *IC*~*50*~ inhibitory concentration, *TLC* total lethal concentration

### Observation and examination items {#Sec7}

#### Clinical signs {#FPar1}

During the test, post treatment observation was done once in a day to monitor the signs of clinical toxicity and/or death.

#### Feed and water consumption {#FPar2}

Feed and water consumption was recorded daily after the starting date of treatment, was calculated from the differences between the supplied amounts and the remaining amounts.

#### Animal behaviour and body weight {#FPar3}

Every two days after injection, rats were weighed and assessed for behavioral changes.

### Hematological indices {#Sec8}

Using a standard saphenous vein blood collection technique, blood was drawn for hematology analysis (using potassium-methylenediaminetetraacetic acid collection tubes). According to the standard hematologic analysis 300 μl of blood was collected from the rat and on 14 and 28 days standard hematologic parameters, i.e, platelet count, hematocrit, hemoglobin, red blood cell count, and white blood cell count were analyzed \[[@CR33]\].

### Biochemistry panel analysis of serum {#Sec9}

To determine the serum biochemical levels including the alanine aminotransferase (ALT/GPT), creatinine (CRE), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), control and treated rats were sacrificed and whole blood samples were collected for centrifugation (3000 rpm) for 15mins. Assessment was performed by an automatic biochemical analyzer for 14 and 28th day's samples \[[@CR34]\].

### Detection of organelles weight {#Sec10}

After 14 and 28 days, the rats were anesthetized by ether with phosphate-buffered saline and were dissected. Organs of the control and treated groups were harvested immediately. Heart, lung, thymus, brain, kidney, liver and spleen were separated carefully and washed with sodium chloride solution and rinsed with ice-cold deionized water and dried with filter paper. Morphology and color of dissected organs were investigated and weight of each organ was measured. To examine the grade of changes explicitly caused by Bio-Cu and ZnONPs, the Organ index (O~*X*~) was calculated separately by using formula \[[@CR35]\]:$$\documentclass[12pt]{minimal}
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Where Organ Index (O~X~) may change as:

Heart index (H~X~), Liver index (Li~X~), Spleen index (S~X~), Lung index (Lu~X~), Kidney index (K~X~), Thymus index (T~X~), Brain index (B~X~).

### Histology {#Sec11}

One rat from each group including control was fixed with 10% buffered formalin following phosphate-buffered saline exsanguinations. A small piece of liver, kidney, spleen and brain was fixed by 10% formalin and embedded into paraffin. Paraffin blocks were sectioned and processed for hematoxylin and eosin staining. Stained sections were observed using bright field microscopy \[[@CR36]\].

### Statistical analysis {#Sec12}

All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per group.

Results and Discussion {#Sec13}
======================

Synthesis of Bio-CuNPs and Bio-ZnONPs were carried out by extracellular enzymatic method during exposure of reactants to *Enterococcus faecalis* supernatant. FeSEM analysis of Bio-CuNPs and Bio-ZnONPs can be seen with size ranging from 1 to 100 nm in distribution (Additional file [1](#MOESM1){ref-type="media"}). TEM analysis reports the presence of biosynthesized CuNPs and ZnONPs with core shell morphology of size 12--90 nm and spherical in shape for CuNPs \[[@CR31]\] and ZnONPs ranging from 16 to 96 nm \[[@CR32]\] (Additional file [2](#MOESM2){ref-type="media"}).

Evaluation of Bio-Cu and ZnONPs on male wistar rats was investigated with no sign of mortality upon NP treatment. Furthermore, after the treatment and till the end of experiment duration frequent examination of white feces was monitored after i/v administration of Bio-CuNPs at 9.5 to 11.5 μg/kg dosage. Between third and fourth week, Bio-CuNPs' treated rats have showed significant rise in feed and water consumption for i/v was 9.5 μg/kg (IC~50~) and 11.5 μg/kg (TLC) whereas for i/p route(dose range: 24.8 to 30.3 μg/kg) and control group rats from 3rd to 4th week.Variation in the body weight of rats after i/v and i/p administration of Bio-CuNPs and Bio-ZnONPs was shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}.Reduction and increase in the body weight are valuable indicators in assessing the toxicity of a test sample \[[@CR37]\]. Previous reports evidenced in toxicity studies on 13.5 nm gold \[[@CR33]\] and 100 nm silver \[[@CR38]\] NPs effect on body weight by i/v injection was less than i/p and oral administration. According Rhiouani et al.*,* the low decrease in weight after 4 days of treatment in all of the treated groups can suggest adverse effects of toxic substances on the animals \[[@CR39]\].Table 3Body weight changes for rat treated with Bio-CuNPs and Bio-ZnONPs through intravenous route of administrationDays after injectionGroup I: Bio-CuNPs' body weight (g)Group II: Bio-ZnONPs' body weight (g)ControlNOAECIC~50~TLCNOAECIC~50~TLCBody weight (g)1100 ± 7.74100 ± 6.65100 ± 6.43100 ± 3.75100 ± 6.89100 ± 4.83100 ± 5.562100 ± 4.43100 ± 5.4398.5 ± 5.73100 ± 05.73100 ± 5.54100.5 ± 4.93100 ± 6.454105.4 ± 5.76102 ± 7.7596.2 ± 4.93102 ± 4.0106.2 ± 5.78102.4 ± 5.93106 ± 5.516108.3 ± 6.92104 ± 3.3296 ± 5.93103.6 ± 5.84106.5 ± 4.93104.8 ± 5.81105 ± 5.37896.5 ± 3.84102 ± 6.8494.8 ± 4.75108 ± 5.83105.1 ± 5.21104.8 ± 6.83108 ± 6.481095.3 ± 4.73100 ± 5.9390.6 ± 3.94108.2 ± 6.75106.8 ± 4.83104.6 ± 4.83112 ± 4.761295 ± 5.84100 ± 4.9988.6 ± 2.4104.2 ± 5.93106.6 ± 5.99104.8 ± 6.93116 ± 5.61495.3 ± 4.0598.5 ± 5.3288 ± 3.2109.2 ± 4.9104.5 ± 6.084105.25 ± 4.83116 ± 6.711698.6 ± 4.7496.4 ± 4.9584.2 ± 4.095109.5 ± 6.55102.7 ± 6.032105.8 ± 5.897121 ± 7.561898 ± 5.8492.3 ± 3.9980.8 ± 3.83109.8 ± 6.4102 ± 7.083106.2 ± 7.54121 ± 8.532096.5 ± 4.7590.7 ± 4.7380 ± 3.73110.7 ± 5.83103.5 ± 6.65104.8 ± 5.95121 ± 5.422298 ± 3.8388.5 ± 3.9375.5 ± 4.94114.6 ± 6.93104.8 ± 4.4103.7 ± 6.84121 ± 6.342498 ± 6.8488 ± 2.7373.7 ± 4.93115.8 ± 6.43107.7 ± 5.32102.5 ± 5.93124 ± 4.32695.6 ± 4.9582.3 ± 4.7570.4 ± 4.04117.2 ± 4.23108.45 ± 6.83100.02 ± 3.65124 ± 5.822895.5 ± 3.9580.9 ± 3.6568.9 ± 3.93119.5 ± 5.73110.7 ± 4.6102.65 ± 3.84124 ± 6.568All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per groupTable 4Body weight changes for rat treated with Bio-CuNPs and Bio-ZnONPs through intraperitoneal route of administrationDays after injectionGroup I: Bio-CuNPs' body weight (g)Group II: Bio-ZnONPs' body weight (g)ControlNOAECIC~50~TLCNOAECIC~50~TLCBody weight (g)1100 ± 5.2100 ± 6.73100 ± 8.3100 ± 5.21100 ± 5.26100 ± 6.94100 ± 5.232100.2 ± 6.63100 ± 7.99100.5 ± 5.28100.4 ± .6.54100.25 ± 6.5100 ± 6.32102 ± 6.7499.7 ± 6.94102.6 ± 7.07399.4 ± 7.83101.7 ± 6.66100.7 ± 6.399.8 ± 4.21102 ± 7.84698.4 ± 7.73102.3 ± 9.09399.2 ± 7.94101.8 ± 7.2199.7 ± 4.199.56 ± 3.75105 ± 8.8899.7 ± 5.45100.2 ± 8.70297.3 ± 5.45102.2 ± 5.6499.6 ± 3.9398.6 ± 4.03106 ± 7.3210100.8 ± 4.8499.3 ± 5.8897.6 ± 6.35104.8 ± 8.21100.67 ± 8.597.23 ± 3.2106 ± 5.4612102.7 ± 6.3399.3 ± 6.9396.2 ± 7.44106.2 ± 6.94100.8 ± 7.396.8 ± 5.3108 ± 6.9414100 ± 7.2198 ± 7.396.3 ± 5.95106.7 ± 7.7498.4 ± 4.694.5 ± 6.86108 ± 6.4216102 ± 6.42101.5 ± 6.4597.7 ± 6.83107 ± 6.297.43 ± 3.496.6 ± 4.31110 ± 5.6718104 ± 4.73102.7 ± 8.3298.3 ± 5.79108.5 ± 8.0598.7 ± 5.598.5 ± 5.94110 ± 7.1220106 ± 5.88104 ± 5.698.6 ± 4.67110.2 ± 7.3497.2 ± 5.396.7 ± 4.7112 ± 5.0922105.4 ± 6.063102.4 ± 9.599.2 ± 3.45112.5 ± 6.21100.3 ± 6.7499.6 ± 4.43114 ± 6.5624106.7 ± 7.83103.8 ± 5.6100 ± 5.23112.6 ± 5.92102.6 ± 7.299.7 ± 3.78118 ± 7.5826107.3 ± 6.08103 ± 5.7100.5 ± .6.05114.5 ± 7.12103.23 ± 6.78100.5 ± 5.34119 ± 4.5328109.4 ± 5.73105.7 ± 7.6102.9 ± 6.85117.8 ± 8.49104.45 ± 5.5499.8 ± 4.95120 ± 6.25All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per group

It can be seen that i/v and i/p administration of Bio-ZnONPs in the three different doses (NOAEC, IC~50~ and TLC) body weight was slightly reduced up to second week of administration compared with the control group. However, after 14th day body weight was regained. In case of i/p administration, reduction in body weight was induced by Bio-ZnONPs (30.3 μg/kg) at total lethal concentration and was lower than control group, thus indicating trivial toxicity via i/p route over the i/v route(Table [4](#Tab4){ref-type="table"}, Fig. [1a](#Fig1){ref-type="fig"}). Similarly, rats treated with Bio-CuNPs, at 9.5 μg/kg and 11.7 μg/kg concentration via i/v route slight reduction in the body weight was noticed. Till 14 days treatment with Bio-CuNPs no sign adverse effects on growth and body weight gain were observed. Body weight variation within 28 days at a dose of 11.7 μg/kg (i/v route) is shown in Table [3](#Tab3){ref-type="table"}. After 14th day of treatment, it was found considerable decrease in body weight via i/v route when compared with the control group. Thus, indicates toxicity of Bio-CuNPs via this route (Fig. [1b](#Fig1){ref-type="fig"}). Bio-CuNPs treated rats via i/p route administration induced minor decrease in body weight and no sign of mortality was observed in both i/p and i/v routes. Therefore, i/p injections induced lower toxicity (shown in Table [4](#Tab4){ref-type="table"} and Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1Change in body weight of untreated (control) and treated rats with Bio-CuNPs and Bio-ZnONPs. Bio-CuNPs and Bio-ZnONPs treated through (A) intraperitoneal (i/p) and (B) intravenous (i/v) route of administration up to 28th day of observation. All treatments of Bio-CuNPs (Cu) and Bio-ZnONPs (ZnO) at their total lethal concentration were administered and kept in observation for 28 days; *N* = 6 rats per group

Hematology indices {#Sec14}
------------------

Estimation of hematologic parameters such as, RBC count, WBC count, platelet count, hemoglobin level and blood clotting time are the important entities to measure the toxicity of treated NPs. For day 14 and 28, concentration-dependent hematology results arepresented in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} for i/p and i/v route of administration. Dosage of Bio-CuNPs at 9.5 μg/kg (IC~50~) and 11.7 μg/kg (TLC) via i/v route has shown reduced RBC count in contrast to Bio-ZnONPs. However, concentration-dependent trend has not been noticed. For rats treated with Bio-ZnONPs through i/v route of administration, hemoglobin level, platelet count, and white blood cells have changed, but no significant difference is observed among all three concentrations (NOAEC, IC~50~ and TLC). But in case of i/p route of administration, significant decrease and changes in red blood cell count, white blood cells, hemoglobin level and platelet count has been found on 14th day of observation (Table [5](#Tab5){ref-type="table"}) as compared to the control and Bio-CuNPs treated. Surprisingly, hematologic effects are found to be normal on 28th day (Table [6](#Tab6){ref-type="table"}).Table 5Haematology study for rat treated with Bio-CuNPs and Bio-ZnONPs through intravenous and intraperitoneal route of administration after 14th day of observationParametersGroup I: Bio-CuNPsGroup II: Bio-ZnONPsControlRef. rangeNOAECIC~50~TLCNOAECIC~50~TLCWBC i/v10.4 ± 0.762.46 ± 0.01511.94 ± 0.5310.45 ± 0.5310.8 ± 0.699.7 ± 0.829.71 ± 0.984--10 i/p9.7 ± 0.643.08 ± 0.05312.5 ± 0.62910.1 ± 0.729.38 ± 0.7910.84 ± 0.4439.82 ± 0.094RBC i/v4.51 ± 0.0432.82 ± 0.0811.2 ± 0.075.81 ± 0.384.95 ± 0.585.23 ± 0.644.98 ± 0.0723.50--5.50 i/p5.174 ± 0.74.05 ± 0.0395.94 ± 0.0435.56 ± 0.0534.65 ± 0.0133.12 ± 0.324.67 ± 0.053Hb i/v129 ± 5.8392 ± 3.6115 ± 5.86152 ± 5.7152 ± 5.39158 ± 4.3127 ± 5.32110--160 i/p103.64 ± 6.9100 ± 3.88144 ± 3.64131 ± 4.5142 ± 3.92160 ± 6.69132 ± 4.054Platelet Count i/v45 ± 4.5321 ± 2.5435 ± 6.3276 ± 6.2253 ± 6.7238 ± 5.8232 ± 5.3100--300 i/p208 ± 6.43106.2 ± 4.255.8 ± 3.96280 ± 5.8310 ± 7.5322 ± 6.65245 ± 4.5Clotting time i/v7.2 ± 0.00658.4 ± 0.0050.7 ± 0.00835.2 ± 0.00174.8 ± 0.00634.72 ± 0.00326.6 ± 0.0122--5 i/p4.2 ± 0.00171.8 ± 0.00157.5 ± 0.00645.7 ± 0.00745.3 ± 0.00415.5 ± 0.00835.9 ± 0.005All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per group*i/v* intravenous route, *i/p* intraperitoneal route, *NOAEC* no observable adverse effect concentration, *IC*~*50*~ inhibitory concentration, *TLC* total lethal concentration, *WBC* white blood cells (SI unit 10^9^/L), *RBC* red blood cells (SI unit 10^9^/L), *Hb* haemoglobin (SI unit g/L) and platelet count (SI unit 10^9^/L), clotting time: in minutesTable 6Haematology study for rat treated with Bio-CuNPs and Bio-ZnONPs through intravenous and intraperitoneal route of administration after 28th day of observationParametersGroup I: Bio-CuNPsGroup II: Bio-ZnONPsControlRef. rangeNOAECIC~50~TLCNOAECIC~50~TLCWBC i/v12.4 ± 0.0893.8 ± 0.03910.6 ± 0.0059.5 ± 0.0699.7 ± 0.00899.93 ± 0.0727.67 ± 0.0434--10 i/p8.2 ± 0.0627.6 ± 0.0579.8 ± 0.01710 ± 0.0749.45 ± 0.08310.2 ± 0.0377.23 ± 0.032RBC i/v5.6 ± 0.823.82 ± 0.0812.2 ± 0.074.8 ± 0.0275.5 ± 0.00835.18 ± 0.00325.2 ± 0.0053.50--5.50 i/p4.174 ± 0.0334.6 ± 0.0866.6 ± 0.0795.18 ± 0.00715.57 ± 0.0656.2 ± 0.0844.94 ± 0.027Hb i/v30.7 ± 2.798.5 ± 4.72120 ± 6.52158 ± 4.57154.6 ± 5.4150 ± 5.83134.5 ± 5.76110--160 i/p130.1 ± 4.83134.7 ± 6.79142.4 ± 6.4143.7 ± 5.63145.8 ± 3.89154.4 ± 7.65137.8 ± 4.93Platelet Count i/v52 ± 2.8334.9 ± 3.6356.8 ± 5.93280 ± 2.83284 ± 5.45256.9 ± 4.29247.2 ± 7.52100--300 i/p273.8 ± 4.95258.2 ± 5.7273.9 ± 3.44284 ± 5.57288.9 ± 6.93294.3 ± 6.076278.4 ± 6.06Clotting time i/v7 ± 0.948.3 ± 0.740.89 ± 0.644.92 ± 0.934.9 ± 0.64.7 ± 0.0435.5 ± 0.062--5 i/p4.5 ± 0.251.5 ± 0.737.2 ± 0.865 ± 0.645.17 ± 0.095 ± 0.0855.6 ± 0.03All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per group*i/v* intravenous route, *i/p* intraperitoneal route, *NOAEC* no observable adverse effect concentration, *IC*~*50*~ inhibitory concentration, *TLC* total lethal concentration, *WBC* white blood cells (SI unit 10^9^/L), *RBC* red blood cells (SI unit 10^9/^L), *Hb* haemoglobin (SI unit g/L) and platelet count (SI unit 10^9^/L), clotting time: in minutes

The hematologic effects of the different injection methods (i/v, i/p) for the two different Bio-NPs on 14th and 28th day of observations are diverse. It can be observed that hemoglobin, red blood cells, white blood cells and platelets decrease via i/v route in Bio-CuNPs treatment and via i/p route in Bio-ZnONPs treated rats. But the significant decrease in RBC counts was observed. This indicates that the different injection routes did not induce significant differences in platelet count, hemoglobin, or white blood cells except in rats injected with Bio-CuNPs (i/v route). Red blood cells show a significant difference after i/p and i/v injection (as shown in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}).

Biochemical assay of serum {#Sec15}
--------------------------

Serum creatinine is waste product; higher creatinine production indicates kidney damage. Bio-ZnONPs (i/v route: dosage of 11-16 μg/kg, i/p route: dosage of 24-30 μg/kg) not significantly affected serum creatinine level when compared with control on 14th and 28th day. (Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}, Fig. [2a, b](#Fig2){ref-type="fig"}). Rats treated with Bio-CuNPs (i/v route: dosage of 06-12 μg/kg) have showed increase in serum creatinine level to 2.3 mg/dl when compared with control. However,i/p route of injection did not showed significant changes (Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}). The blood serum has large number of enzymes but to assess the normal and pathological symptoms of liver, alanine transaminse (glutamate pyruvate transaminase) and aspartate transaminases (glutamate oxalate acetate transaminase) are useful. Aspartate transaminase is of mitochondrial origin present in large quantities in liver, heart, kidney and skeletal muscles. Serum alkaline phosphatase is a globulin enzyme of low molecular weight, found in higher concentration in bones, hepatobiliary tract and kidney. The activity of this enzyme can be determined by the estimation of organic phosphate liberated from the glycerol phosphate. The serum level of the enzymes was increased in both hepatocellular and obstructive Jaundice. In the i/v route of administration, Bio-ZnONPs (40.7 mg/dl, 37.9 IU/L, 82.4 IU/L) no significanteffects on serum ALT, serum AST and ALP levels as compared with control. Although i/p administration showed significant increase in ALT, AST and ALP level as compared with control at 14th and 28th day (Fig. [2a and b](#Fig2){ref-type="fig"}). Results of toxicity study on serum showed Bio-ZnONPs no changes in the levels of creatinine, ALT, AST and ALP levels for i/v route till 28 days.Table 7Biochemical assays for rat treated with Bio-CuNPs and Bio-ZnONPs through intraperitoneal and intravenous route of administration for 14th day of observationTestsGroup I: Bio-CuNPsGroup II: Bio-ZnONPsControlRef. rangeNOAECIC~50~TLCNOAECIC~50~TLCS. creatinine i/v0.9 ± 0.0831.5 ± 0.0672.3 ± 0.0350.7 ± 0.0430.6 ± 0.0750.78 ± 0.0740.92 ± 0.0230.7--1.4 i/p0.72 ± 0.0760.75 ± 0.0870.9 ± 0.0230.83 ± 0.0680.93 ± 0.0740.9 ± 0.0730.89 ± 0.056ALT i/v35.2 ± 3.7544.6 ± 2.7467.7 ± 3.8412.7 ± 4.6432.8 ± 3.5440.7 ± 4.3238.5 ± 4.850.0--40.0 i/p30.8 ± 2.5635.7 ± 4.4540.3 ± 2.7517.8 ± 3.9220.8 ± 4.7345.9 ± 2.4335.2 ± 3.15AST i/v27.3 ± 2.6530.8 ± 3.7770 ± 2.7824.6 ± 3.6730.7 ± 2.4337.9 ± 3.5125.2 ± 3.185.0--34.0 i/p20.8 ± 3.2324.9 ± 4.7826.7 ± 3.5617.4 ± 1.9320.8 ± 2.8439.8 ± 2.5720.7 ± 4.72ALP i/v75.8 ± 4.4384.8 ± 2.85116.8 ± 3.3875.8 ± 2.8978.9 ± 3.1782.4 ± 3.8578.5 ± 2.3837--103 i/p83.9 ± 3.6898.3 ± 3.43113.7 ± 4.8572.8 ± 3.6480.8 ± 2.94100.8 ± 4.9386.3 ± 3.5All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per group*i/v* intravenous route, *i/p* intraperitoneal route, *NOAEC* no observable adverse effect concentration, *IC*~*50*~ inhibitory concentration, *TLC* total lethal concentration, S. creatinine (mg/dl), *ALT* alanine aminotransferase (IU/L), *AST* aspartate aminotransferase (IU/L), *ALP* alkaline phosphatase (IU/L)Table 8Biochemical assays for rat treated with Bio-CuNPs and Bio-ZnONPs through intraperitoneal and intravenous route of administration for 28th day of observationTestsGroup I: Bio-CuNPsGroup II: Bio-ZnONPsControlRef. rangeNOAECIC~50~TLCNOAECIC~50~TLCS. creatinine i/v0.95 ± 0.0731.7 ± 0.0572.34 ± 0.0350.7 ± 0.0610.72 ± 0.0590.8 ± 0.0580.82 ± 0.0620.7--1.4 i/p0.9 ± 0.0381.48 ± 0.0931.52 ± 0.0850.8 ± 0.0790.92 ± 0.0930.89 ± 0.0620.93 ± 0.083ALT i/v37.5 ± 1.8246.8 ± 1.4470.6 ± 2.7322.1 ± 2.8134.2 ± 3.9840.7 ± 3.3225.8 ± 2.640.0--40.0 i/p35.8 ± 2.03237.8 ± 3.9341.6 ± 3.6420.9 ± 0.06722.8 ± 2.7442.9 ± 4.3230.9 ± 3.93AST i/v28.2 ± 3.8236.5 ± 5.1684.7 ± 2.927.8 ± 5.4432.7 ± 4.8439.5 ± 4.827.8 ± 2.295.0--34.0 i/p26.3 ± 3.8328.2 ± 2.1733.9 ± 4.8228.3 ± .3.7730.8 ± 3.5138.7 ± 3.228.7 ± 0.063ALP i/v73.7 ± 3.3890.8 ± 2.63128.7 ± 5.9375.3 ± 3.8380.6 ± 3.7984.7 ± 3.772.8 ± 2.7537--103 i/p84.2 ± 4.84100.2 ± 5.79132.7 ± 3.3674.7 ± 2.8884.8 ± 4.6898.8 ± 2.8284.2 ± 3.68All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per group*i/v* intravenous route, *i/p* intraperitoneal route, *NOAEC* no observable adverse effect concentration, *IC*~*50*~ inhibitory concentration, *TLC* total lethal concentration, S. Creatinine (mg/dl), *ALT* alanine aminotransferase (IU/L), *AST* aspartate aminotransferase (IU/L), *ALP* alkaline phosphatase (IU/L)Fig. 2Biochemical results of rats treated with Bio-CuNPs and Bio-ZnONPs. S. creatinine, ALT, AST and ALP levels were measured in rats treated with Bio-CuNPs and Bio-ZnONPs through intraperitoneal (i/p) and intravenous (i/v) route of administration on (A) 14th day and (B) 28th day. All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per group. Note: Cu: Bio-CuNPs, ZnO: Bio-ZnONPs, i/p: intraperitoneal, i/v: intravenous

In contrast, rats treated with Bio-CuNPs through i/v route, showed significant increase in serum ALT (67.7 mg/dl), AST level (70 IU/L), and ALP (128 IU/L). Effect of Bio-CuNPs through i/p route was considerably low compared to control. The difference of the results could be attributed to difference in the dosage routes, toxicity of nanoparticles as well as the duration of administration. We found Bio-ZnONPs have no effect on kidney and liver function biomarkers (both i/v and i/p) as compare to Bio-CuNPs.

Detection of organelles weight and histological study {#Sec16}
-----------------------------------------------------

Changes in the organ weights of rat at different Bio-NPs doses, illustrate the adverse effects of NPs on organs. It can be seen that the weights of the heart, liver, spleen, lung, kidneys, and brain are decreased in rats when treated with Bio-ZnONPs as depicted in Tables [9](#Tab9){ref-type="table"} and [10](#Tab10){ref-type="table"}. Furthermore, consideration of the organ reaction and grade of changes were examined by calculating organ index (O~X~) of each organ separately. The organ index for heart, liver, spleen, lung, kidneys, brain and thymus are presented in Tables [9](#Tab9){ref-type="table"} and [10](#Tab10){ref-type="table"}.Table 9Weight of organs or organ index (O~X~) for rat treated with Bio-CuNPs and Bio-ZnONPs through intraperitoneal and intravenous route of administration for 14th day of observationTestsGroup I: Bio-CuNPsGroup II: Bio-ZnONPsControlNOAECIC~50~TLCNOAECIC~50~TLCHeart (H~X~) i/v0.96 ± 0.060.48 ± 0.070.22 ± 0.0751.1 ± 0.041.03 ± 0.0651.25 ± 0.0241 ± 0.02 i/p1.9 ± 0.091.25 ± 0.03441.143 ± 0.0231.23 ± 0.0320.98 ± 0.0770.94 ± 0.0651.4 ± 0.05Liver (Li~X~) i/vI.25 ± 0.0430.92 ± 0.060.48 ± 0.0491.67 ± 0.0261.56 ± 0.0931.47 ± 0.0861.8 ± 0.043 i/p1.44 ± 0.051.23 ± 0.081.08 ± 0.0991.54 ± 0.071.34 ± 0.0321.27 ± 0.02891.67 ± 0.032Spleen (S~X~) i/v0.59 ± 0.070.47 ± 0.090.265 ± 0.0431.45 ± 0.0190.97 ± 0.0060.87 ± 0.0541.16 ± 0.028 i/p087 ± 0.010.63 ± 0.0540.58 ± 0.0521.38 ± 0.0540.66 ± 0.0530.65 ± 0.0391.18 ± 0.067Lungs (Lu~X~) i/v0.87 ± 0.0650.77 ± 0.0760.42 ± 0.0812.14 ± 0.098.78 ± 0.0331.54 ± 0.0441.56 ± 0.082 i/p0.86 ± 0.0860.67 ± 0.0120.75 ± 0.0932.06 ± 0.120.94 ± 0.0540.78 ± 0.0671.72 ± 0.028Kidneys (K~X~) i/v0.64 ± 0.030.5 ± 0.0430.35 ± 0.0732.4 ± 0.1562.10 ± 0.0281.78 ± 0.0261.23 ± 0.099 i/p0.83 ± 0.060.8 ± 0.0530.65 ± 0.0431.98 ± 0.0870.34 ± 0.0540.88 ± 0.0581.52 ± 0.091Thymus (T~X~) i/v0.21 ± 0.090.18 ± 0.0270.11 ± 0.0530.167 ± 0.0340.15 ± 0.0340.142 ± 0.0940.18 ± 0.076 i/p0.2 ± 0.030.22 ± 0.0360.18 ± 0.090.178 ± 0.0530.112 ± 0.0280.13 ± 0.0270.16 ± 0.045Brain (B~X~) i/v1.92 ± 0.050.72 ± 0.0720.75 ± 0.0012.3 ± 0.0441.76 ± 0.0951.54 ± 0.0791.89 ± 0.092 i/p1.76 ± 0.0861.25 ± 0.0581.22 ± 0.0642.1 ± 0.0751.21 ± 0.0531.02 ± 0.0911.72 ± 0.087All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per groupTable 10Weight of organs or organ index (O~X~) for rat treated with Bio-CuNPs and Bio-ZnONPs through intraperitoneal and intravenous route of administration for 28th day of observationTestsGroup I: Bio-CuNPsGroup II: Bio-ZnONPsControlNOAECIC~50~TLCNOAECIC~50~TLCHeart (H~X~) i/v0.94 ± 0.0030.8 ± 0.00210.67 ± 0.0031.5 ± 0.00561.24 ± 0.00481.45 ± 0.00871.4 ± 0.094 i/p1.69 ± 0.0051.65 ± 0.00671.43 ± 0.0041.45 ± 0.00781.23 ± 0.00541.14 ± 0.00951.32 ± 0.037Liver (Li~X~) i/v1.27 ± 0.00530.99 ± 0.00320.67 ± 0.00431.77 ± 0.00641.66 ± 0.0051.59 ± 0.00781.8 ± 0.005 i/p1.48 ± 0.0831.32 ± 0.0081.18 ± 0.00271.69 ± 0.00431.45 ± 0.09521.2 ± 0.00741.78 ± 0.090Spleen (S~X~) i/v0.67 ± 0.00450.53 ± 0.0530.49 ± 0.0041.35 ± 0.00671.23 ± 0.00341.16 ± 0.00431.2 ± 0.004 i/p1.87 ± 0.0671.63 ± 0.0031.52 ± 0.00871.58 ± 0.0541.56 ± 0.00341.04 ± 0.00371.8 ± 0.0058Lungs (Lu~X~) i/v1.4 ± 0.0831.56 ± 0.00561.18 ± 0.00672.1 ± 0.00651.99 ± 0.00651.58 ± 0.00561.59 ± 0.0043 i/p1.86 ± 0.0061.61 ± 0.00781.24 ± 0.00642.17 ± 0.0311.94 ± 0.00431.58 ± 0.00741.68 ± 0.005Kidneys (K~X~) i/v1.64 ± 0.0851.2 ± 0.0561.13 ± 0.00672.3 ± 0.0632.52 ± 0.00832.17 ± 0.00671.7 ± 0.0093 i/p1.63 ± 0.0931.23 ± 0.00670.95 ± 0.00842.67 ± 0.00341.78 ± 0.00890.98 ± 0.00521.6 ± 0.0031Thymus (T~X~) i/v0.158 ± 0.0040.124 ± 0.0660.11 ± 0.00430.164 ± 0.00530.16 ± 0.00420.157 ± 0.00340.16 ± 0.0073 i/p0.21 ± 0.00520.23 ± 0.00820.21 ± 0.00650.175 ± 0.00980.169 ± 0.00630.15 ± 0.00890.174 ± 0.0065Brain (B~X~) i/v1.92 ± 0.0-760.78 ± 0.00670.76 ± 0.00562.18 ± 0.00641.97 ± 0.00781.85 ± 0.00371.92 ± 0.045 i/p1.92 ± 0.0541.67 ± 0.00321.32 ± 0.00532.6 ± 0.00561.92 ± 0.00531.73 ± 0.00631.85 ± 0.0074All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, *N* = 6 rats per group

Difference in the weight of spleen and thymus were observed after i/v and i/p administration in Bio-CuNPs and Bio-ZnONPs treated rats. On 14th day, Bio-ZnONPs has shown decreased spleen index via i/p injection, and increased by i/v administration (Table [9](#Tab9){ref-type="table"}). In case of Bio-CuNPs treated rats via i/v administration showed significant reduction in spleen index on 14th (0.265) and 28th day (0.49). Thus indicating, the immune system has been affected by i/v Bio-CuNPs administration and i/p Bio-ZnONPs administration. In case of, i/p Bio-ZnONPs administration, immune system of rat is recurring to the normal state after 14th day and proves the effect is not prolonged. Taken together with the previous body weight variation, it seems that i/v administration route of Bio-CuNPs can affect the heart, liver, lung, kidneys, and brain; furthermore it might damage the immune system. From Fig. [3a](#Fig3){ref-type="fig"}, it implies spleen and thymus are main target of organs by Bio-CuNPs.Fig. 3Change in organelle morphology. Where **a** spleen, **b** liver, **c** kidney, **d** brain, **e** lungs and **f** heart, of male Wistar rats treated with Bio-CuNPs via intravenous route in comparison with control on 28th day observation

In case of i/v and i/p Bio-CuNPs treated groups obvious effects on organ index has been observed at both IC~50~ and TLC doses. Moreover, of the two different administration routes, the intraperitoneal injection show the modest toxicity in Bio-ZnONPs treated groups and highest toxicity in Bio-CuNPs treated groups. Efficient drug absorption by i/p injection was known to be rapid due to the dense blood vessels and lymph in the murine peritoneum \[[@CR40]\]. Correspondingly, the intravenous injection shows the least toxicity in Bio-ZnONPs treated groups and highest toxicity in Bio-CuNPs treated groups.

Toxicological changes in rats {#Sec17}
-----------------------------

We tried to scrutinize the effects of toxicity, at different doses and time intervals of Bio-NPs. Tissues treated with Bio-ZnONPs (i/v route: dosage range 11-16 μg/kg, i/p route: dosage range 24-30 μg/kg) showed no changes in the liver, kidney, spleen and brain when compared with control tissues (Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}). Necropsy observations (autopsy: dissective examination of dead rat) specified that all organs of Bio-NPs treated rats exhibited the anatomic features (e.g., characteristics of color, shape, and size) to be expected based on their appearance in untreated animal. As compared to Bio-ZnONPs, Bio-CuNPs treated rats showed more significant changes in anatomic features of kidney, liver, spleen and brain tissues in contrast to control (Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}).Fig. 4H&E-stained sections of rat kidney. Rats treated via i/v and i/p route with Bio-Cu and ZnONPs; untreated samples were considered as control. Where sections treated with Bio-CuNPs observed on day 14 (A--C) and day 28 (D--F). Bio-ZnONPs' treated sections on day 14 (G--I) and day 28 (J--L). BC Bowman capsule, G glomerular, PT proximal tubule, GN glomerular necrosis, PTD proximal tubule damageFig. 5H&E-stained sections of rat spleen. Rats treated via i/v and i/p route with Bio-Cu and ZnONPs; untreated samples were considered as control. Sections treated with Bio-CuNPs observed on day 14 (A--C) and day 28 (D--F). Bio-ZnONPs' treated sections on day 14 (G--I) and day 28 (J--L). WP white pulp, RP red pulp, DRP decline in red pulpFig. 6H&E-stained sections of rat liver. Rats treated via i/v and i/p route with Bio-Cu and ZnONPs; untreated samples were considered as control. Sections treated with Bio-CuNPs observed on day 14 (A--C) and day 28 (D--F). Bio-ZnONPs' treated sections on day 14 (G--I) and day 28 (J--L). CV central vein, KC Kupffer cells, CVV central vein vacuolization (cytoplasmic vacuolization), HH hepatic haemorrhageFig. 7H&E-stained sections of rat brain. Rats treated via i/v and i/p route with Bio-Cu and ZnONPs; untreated samples were considered as control. Sections treated with Bio-CuNPs observed on day 14 (A--C) and day 28 (D--F). Bio-ZnONPs' treated sections on day 14 (G--I) and day 28 (J--L). \[All slides are observed under × 40 magnification, NIKON eclipse E200 (Trinacular microscope)\]

Bio-CuNPs induced damages via i/v route administration and showed dose-dependent trend in tissues. At TLC (11. 7 μg/kg) concentration, Bio-CuNPs showed severe damage to the liver and kidney tissues of Wistar rats. In addition, Bio-CuNPs treated via both i/v and i/p route have induced necrosis of glomerular cells (glomerular atrophy), bowman capsule and proximal tubular in group 14th and 28th day rats (Fig. [4b, e, c](#Fig4){ref-type="fig"} and [f](#Fig4){ref-type="fig"}) when compared to the untreated control. Glomerular necrosis is due to immunological reimbursement, but tubule damages are mostly due to toxic effect of the NPs. The tubular damage caused by the toxic effects of Bio-CuNPs through both i/v and i/p route also increased the glomerular pressure and causes glomerular atrophy.

Normal control group showed normal histological structure of hepatic lobule and the central vein which is surrounded by normal hepatocytes (Fig. [6](#Fig6){ref-type="fig"}). Bio-CuNPs treated via i/p route (19.82 μg/kg) showed mild histological changes including Kupffer cell activation both in 14th and 28th day observation (Fig. [6b, e](#Fig6){ref-type="fig"}). Rats treated with Bio-CuNPs via i/v route showed severe changes including cytoplasmic vacuolization of central vein surrounded hepatocytes and hepatic haemorrhage for 14th day observation (Fig. [6c](#Fig6){ref-type="fig"}). Surprisingly, 28th day group showed moderate changes including fatty changes of hepatocytes and pyknosis of hepatocytic nuclei (Fig. [6f](#Fig6){ref-type="fig"}). Liver tissue treated with Bio-ZnONPs, for 14th day of i/p route administered group, showed moderate changes demonstrated by fatty changes of hepatocytes (Fig. [6i](#Fig6){ref-type="fig"}). Bio-ZnONPs' treated groups showed slight improvement, and significant hepatoprotective activity was observed in 28th day as compared to 14th day (Fig. [6l](#Fig6){ref-type="fig"}). On 14th day onwards, restoration of normal hepatic architecture has taken place in Bio-ZnONPs' treated animals.

A decline in the spleen cell (red pulp), whereas an increase in lymphocytes (white pulp), in spleen tissue extracted from rat treated with Bio-CuNPs via i/v route (Fig. [5c, f](#Fig5){ref-type="fig"}) was noticed. In primary observation, accretion of Bio-CuNPs in the spleen was noticed in the red pulp and was related with a modest loss of cell mass; reduced cell mass was obvious on the 28th day time point when compared with 14th day of i/v administration (Fig. [5f](#Fig5){ref-type="fig"}), whereas minor changes were observed in red pulp depletion when rats were treated with Bio-CuNPs via i/p route on both 14th and 28th day time point. Structural changes were not seen in the white pulp or in splenic blood vessels (arteries or venous sinuses) and intravascular erythrocytes (Fig. [5b, e](#Fig5){ref-type="fig"}). No morphological changes have been found in spleen tissues treated with Bio-ZnONPs (Fig. [5](#Fig5){ref-type="fig"}). The H&E-stained brain sections of rats, treated (i/v and i/p) with NPs, showed no changes in brain region, olfactory bulb (perivascular localization) and the choroid plexus and ependyma of the lateral ventricles (Fig. [7](#Fig7){ref-type="fig"}).

Conclusion {#Sec18}
==========

Animal toxicity studies using 16- to 96-nm-ranged biosynthesized copper (Bio-CuNPs) and zinc oxide (Bio-ZnONPs) was assessed in male Wistar rat at the dose range of 6.1 to 19.82 μg/kg and 11.14 to 30.3 μg/kg respectively for both i/p and i/v routes on 14th and 28th day of observation. We observed no mortality and normal behaviour in the animals treated with Bio-CuNPs and Bio-ZnONPs in their specific dose range. The results also verified the Bio-CuNPs and Bio-ZnONPs at low concentrations do not cause identifiable toxicity even after their breakdown in vivo over time. Increased concentrations of these Bio-NPs induce weight reduction, but no significant statistical difference was observed for Bio-ZnONPs' treated animals. In the case of i/v and i/p Bio-CuNPs' treated groups, obvious effects on organ index have been observed at both IC~50~ and TLC doses. Moreover, of the two different administration routes, the intraperitoneal injection shows the modest toxicity in Bio-ZnONPs' treated groups and highest toxicity in Bio-CuNPs' treated groups. Correspondingly, the intravenous injection shows the least toxicity in Bio-ZnONPs' treated groups and highest toxicity in Bio-CuNPs' treated groups. Considering all the results of studies, targeting Bio-ZnONPs by intravenous injection is promising for possible biomedical application.

Additional file
===============

 {#Sec19}

Additional file 1:**Figure S1.** FeSEM images of Bio-CuNPs from *Enterococcus faecalis* \[[@CR32]\]. Figure S2: FeSEM images of Bio-ZnONPs from *Enterococcus faecalis* \[[@CR37]\]. (DOCX 1058 kb) Additional file 2:**Figure S3**. TEM images of (A) Bio-CuNPs and (B) Bio-ZnONPs synthesized from *Enterococcus faecalis* \[[@CR41]\]. (DOCX 901 kb)
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